drugset / Trial / NCT02667327

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

NCT02667327 ↗

Phase 3 Terminated 124 enrolled Xequel Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.

Timeline

Start
2018-11-21
Primary completion
2020-05-27
Completion
2020-05-27

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision (No safety or efficacy concerns)”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ACT-1 PEPTIDE Peptide 100 unknown Topical

Indications